| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446441 | OTTER PHARMS | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US9533102 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9629959 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US8562564 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US8021335 | OTTER PHARMS | Prefilled syringe jet injector |
Oct, 2026
(3 years from now) | |
| US11684723 | OTTER PHARMS | Injector safety device |
Mar, 2029
(5 years from now) | |
| US9867949 | OTTER PHARMS | Injector safety device |
Mar, 2029
(5 years from now) | |
| US10709844 | OTTER PHARMS | Injector safety device |
Mar, 2029
(5 years from now) | |
| US9421333 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US8480631 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US8945063 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US8579865 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US11497753 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US8814834 | OTTER PHARMS | Injector safety device |
May, 2031
(7 years from now) | |
Otrexup is owned by Otter Pharms.
Otrexup contains Methotrexate.
Otrexup has a total of 14 drug patents out of which 0 drug patents have expired.
Otrexup was authorised for market use on 11 October, 2013.
Otrexup is available in solution;subcutaneous dosage forms.
Otrexup can be used as subcutaneous injection of methotrexate.
The generics of Otrexup are possible to be released after 27 May, 2031.
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 11 October, 2013
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
OTREXUP family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic